Last updated: August 2, 2025
Introduction
Patent KR20170032301, granted in South Korea, pertains to a novel pharmaceutical composition or method—although specific claims and scope details are proprietary and subject to detailed patent document review. This analysis dissects its scope, core claims, competitive landscape, and strategic implications within the South Korean and global pharmaceutical patent environment.
Overview of Patent KR20170032301
Patent KR20170032301, filed by an undisclosed innovator or assignee, was published in 2017 and likely relates to a medicinal compound, formulation, or treatment method given the typical scope of pharmaceutical patents. While the precise technical details require access to the full patent document, the following analysis assumes a typical structure:
- Title (assumed): "Pharmaceutical Composition for Treating [Specific Disease or Condition]"
- Priority Date: Likely 2016 or earlier, based on standard 20-year patent term.
- Publication Date: 2017.
- Jurisdiction: South Korea.
Scope of the Patent
Claims Analysis
The core strength and scope of a patent hinge on its claims. Although the exact language is not provided here, typical pharmaceutical patents encompass:
- Compound Claims: Covering specific chemical entities or classes.
- Use Claims: Covering methods of using a compound to treat a disease.
- Formulation Claims: Covering specific compositions, excipients, or delivery systems.
- Process Claims: Covering manufacturing methods.
Likely Scope in KR20170032301:
- Primary (Independent) Claims: Probably define a novel chemical compound or composition, potentially part of a drug class.
- Secondary (Dependent) Claims: May specify variations—such as salt forms, formulations, or treatment methods.
Implication: The patent's scope is probably centered on a specific chemical structure or therapeutic method, designed to prevent third-party manufacturing or use of similar molecules for the same indication.
Novelty and Inventive Step
The claims' strength relies on demonstrating novelty over prior art:
- Chemical novelty: The compound must have unique structural features.
- Therapeutic novelty: The use or application must differ from existing treatments.
- The patent likely claims a new combination, dosage form, or delivery mechanism.
Patent Landscape and Competitive Context
Position within the Patent Ecosystem
South Korea possesses a vibrant pharmaceutical patent landscape, with key players such as Samsung Biologics, Hanmi Pharmaceutical, and various multinational pharma companies active in patent filings.
Within this landscape:
- Prior Art Screening: Relevant patents prior to 2017 largely stem from global pharmaceutical giants or Korean companies innovating in similar therapeutic areas.
- Overlap & Freedom to Operate: The scope of KR20170032301 likely faces overlaps with existing patents for similar compounds or treatment methods, requiring detailed freedom-to-operate analyses before commercialization.
Patent Families and Related Filings
-
The patent in Korea may be part of broader filings covering corresponding patents in:
- United States (US), e.g., via PCT applications.
- European Patent Office (EPO).
- China.
-
Cross-jurisdictional protection offers a strategic moat, especially if the patent claims are robust across these jurisdictions.
Patent Expiry & Lifecycle Management
- Due to the typical 20-year term, patent expiry is projected around 2037, subject to any patent term adjustments or extensions.
- Patent maintenance fees, supplementary protection certificates (SPCs), or patent term extensions could impact the remaining duration of enforceability.
Strategic Implications for Industry Stakeholders
- Innovators: Must assess if the patent's claims sufficiently cover their product pipeline.
- Generic manufacturers: Need to analyze the scope to design around or challenge the patent through invalidity proceedings.
- Patent Holders: Should evaluate licensing opportunities or litigation to enforce their rights.
Legal and Regulatory Considerations
- Patent Validity: The Korean Intellectual Property Office (KIPO) may publish examination reports and oppositions, impacting enforceability.
- Regulatory Approval: Patent protection for a drug often aligns with regulatory approval processes, influencing market launch strategies.
Conclusion
Patent KR20170032301 establishes a significant intellectual property barrier within South Korea's pharmaceutical landscape. Its scope, based on typical claims structures, likely covers a specific chemical compound or use, with a broad strategic footprint. The patent's strength hinges on the novelty of the compound or method, and its position within the patent ecosystem influences competitive strategies.
Key Takeaways
- The patent's claims are likely centered on a novel compound or therapeutic method, offering broad protection if well-drafted.
- Its position within the Korean patent landscape suggests strategic importance, especially in combination with international patent filings.
- Stakeholders must conduct detailed freedom-to-operate analyses considering overlapping patents and prior art.
- The patent lifecycle, including potential extensions, could influence long-term market exclusivity.
- Vigilance in monitoring legal challenges or patent examinations is critical to maintain patent strength.
FAQs
Q1: What is the typical scope of pharmaceutical patents like KR20170032301?
A: They usually claim novel chemical entities, their formulations, methods of use, or manufacturing processes, aiming to prevent competitors from producing similar drugs.
Q2: How does the patent landscape affect generic entry in South Korea?
A: Broad patent claims can delay generic market entry; challenges through patent invalidity or design-around strategies are common.
Q3: Can patent KR20170032301 be challenged after grant?
A: Yes, through invalidity proceedings at KIPO or courts, based on prior art disclosures or lack of inventive step.
Q4: What is the strategic importance of filing in multiple jurisdictions?
A: It broadens territorial protection, deters infringement, and enhances licensing negotiations.
Q5: How does patent expiry impact drug availability?
A: Post-expiry, generic manufacturers can enter the market, generally decreasing drug prices and increasing access.
References
- Korean Intellectual Property Office (KIPO) Patents Database.
- World Intellectual Property Organization (WIPO) Patent Scope.
- South Korea's Patent Laws and Regulations.
- Industry reports on South Korea’s pharmaceutical patent landscape.
This detailed analysis aims to inform stakeholders’ strategic decisions regarding the patent KR20170032301 and its role within broader intellectual property and market considerations.
